The condition causes symptoms such as numbness, weakness and pain, mainly affecting the feet, hands, arms and legs.
It can be treated and most people will make a full recovery.
However it can be life-threatening and some people are left with long-term problems.
The EU’s drugs watchdog and other regulators are already reviewing the possibility of rare blood clotting conditions with vaccines, including the AstraZeneca shot.
Some European countries have restricted use of the AstraZeneca jab to older age groups, citing the risks of rare blood clots in younger people.
Meanwhile, the European Commission has launched legal action against the pharmaceutical giant amid a row over jab supplies.
Professor Wei Shen Lim, Covid-19 chairman for JCVI, said: “Safety remains our number one priority.
“We have continued to assess the benefit/risk balance of Covid-19 vaccines in light of UK infection rates and the latest information from the MHRA on the extremely rare event of blood clots and low platelet counts following vaccination.
“The advice is specific to circumstances in the UK at this time and maximises use of the wide portfolio of vaccines available.
“The Covid-19 vaccines have already saved thousands of lives and the benefit for the majority of the population is clear – if you are offered the vaccine, you should take it.”
This post originally appeared on Daily Express :: World Feed